This post was originally published on this site Combining the experimental therapy MDNA55 with anti-cancer interferons (IFNs) can effectively kill cancer cells and extend the survival of mice with metastatic ovarian cancer, new research results show. The study, “Combination immunotherapy with IL-4- Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model…
This post was originally published on this site The U.S. Food and Drug Admnistration (FDA) has agreed to review Sanofi’s biologics license application (BLA) for its investigational antibody, isatuximab, as a potential therapy for patients with hard-to-treat multiple myeloma, the company announced. FDA’s final decision about whether to approve isatuximab is expected by April 30, 2020, according…
This post was originally published on this site I had my six-month checkup with the oncologist a couple of weeks ago. I won’t keep you in suspense: My follicular lymphoma is stable, and things look good. But it was a rough ride getting to the good news. Literally. I made the appointment for 9 a.m.…
This post was originally published on this site Dosing with the investigational therapy TP-0903 has begun in patients with previously treated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in an ongoing Phase 1/2 trial, its developer, Tolero Pharmaceuticals, announced. The open-label study (NCT03572634) aims to recruit 108 patients who have failed to respond to prior therapies.…
This post was originally published on this site Libtayo (cemiplimab) has been conditionally approved to be sold in the European Union for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), one of the most common types of skin cancer. The decision of the European Commission (EC) makes Libtayo the…
This post was originally published on this site A combination of Polyphor‘s investigational therapy balixafortide (POL6326) and Eisai‘s Halaven (eribulin) may prolong the survival of women with HER2-negative metastatic breast cancer, a Phase 1 trial shows. The findings were presented in the poster “Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival…
This post was originally published on this site Caregivers of a certain age may remember the late comedienne Lucille Ball’s “Vitameatavegamin“ sketch. The famous, very funny redhead asks: “Are you tired, rundown, listless? Do you poop out at parties?” For most caregivers, the answer is a resounding “yes,” perhaps especially for those who care for…
This post was originally published on this site An online test, called MemTrax, may help screen and predict the progression of cognitive impairment in Alzheimer’s and other disorders, according to a new study using artificial intelligence. The research, “Episodic-Memory Performance in Machine Learning Modeling for Predicting Cognitive Health Status Classification,” was published in the Journal…
This post was originally published on this site Advantagene, also known as Candel Therapeutics, has reached its patient enrollment goal in an ongoing Phase 2 trial testing the effectiveness of ProstAtak, the company’s prostate cancer vaccine, among men with localized prostate cancer who chose to remain on active surveillance. ProstAtack is a gene-mediated cytotoxic immunotherapy…
This post was originally published on this site After positive feedback from the U.S. Food and Drug Administration, TG Therapeutics is planning to pursue accelerated approval for umbralisib (TGR-1202) as a treatment for patients with marginal zone lymphoma (MZL). The decision was supported by findings from the ongoing UNITY-NHL Phase 2b clinical trial (NCT02793583), in which…
